Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia

Anesthesia and Analgesia

Volumn 106, Issue 2, 2008, Pages 404-408

  Apostolidou, Ioanna ^a   Sweeney, Michael F ^a   Missov, Emil ^a   Joyce, Lyle D ^a   John, Ranjit ^a   Prielipp, Richard C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; APROTININ; DOPAMINE; HEPARIN; HIRULOG; LEPIRUDIN; MILRINONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CASE REPORT; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEART ASSIST DEVICE; HEART ATRIUM THROMBOSIS; HEART FAILURE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 38549166188     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31815edb52     Document Type: Article

References (33)

1. Goldstein DJ, Beauford RB. Left ventricular assist devices and bleeding: adding insult to injury. Ann Thorac Surg 2003;75:S42-7
2. Stevenson LW, Rose EA. Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom? Circulation 2003;108:3059-63
3. Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, Rose E, Schmidt AM. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996;112:1090-7
4. Kasirajan V, McCarthy PM, Hoercher KJ, Starling RC, Young JB, Banbury MK, Smedira NG. Clinical experience with long-term use of implantable left ventricular assist devices: indications, implantation, and outcomes. Semin Thorac Cardiovasc Surg 2000;12:229-37
5. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006;81:36-44
6. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:638-48
7. Bennett-Guerrero E, Slaughter TF, White WD, Welsby IJ, Greenberg CS, El-Moalem H, Ortel TL. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1567-72
8. Kress DC, Aronson S, McDonald ML, Malik MI, Divgi AB, Tector AJ, Downey FX III, Anderson AJ, Stone M, Clancy C. Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 2007;83:1737-43
9. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice. Focus on lepirudin. Circulation. 2001;103:1479-84
10. Wan C, Warner M, De Varennes B, Ergina P, Cecere R, Lachapelle K. Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy. Ann Thorac Surg 2006;82:21-6
11. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131:533-9
12. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:113-26
13. Reilly MP, Wiegers SE, Cucchiara AJ, O'Hara ML, Plappert TJ, Loh E, Acker M, Sutton MStJ. Frequency, risk factors and clinical outcomes of left ventricular assist device-associated ventricular thrombus. Am J Cardiol 2000;86:1156-9
14. Koster A, Huebler S, Potapov E, Meyer O, Jurmann M, Weng Y, Pasic M, Drews T, Kuppe H, Loebe M, Hetzer R. Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single institution experience in 358 consecutive patients. Ann Thorac Surg 2007;83:72-6
15. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002;126:1415-23
16. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6
17. Hach-Wunderle V, Kainer K, Salzmann G, Muller-Berghaus G, Potzsch B. Heparin-related thrombosis despite normal platelet counts in vascular surgery. Am J Surg 1997;173:117-9
18. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003;101:3049 -51
19. Koster A, Chew D, Grundel M, Hausmann H, Grauhan O, Kuppe H, Spiess BD. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 2003;96:1316-9
20. Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006;43(suppl 1):S59-63
21. Goldstein DJ, Seldomridge JA, Chen JM, Catanese KA, DeRosa CM, Weinberg AD, Smith CR, Rose EA, Levin HR, Oz MC. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 1995;59:1063-7
22. Cooper JR, Abrams J, Frazier OH, Radovancevic R, Radovancevic B, Bracey AW, Kindo MJ, Gregoric ID. Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. J Thorac Cardiovasc Surg 2006;131:963-8
23. Shore-Lesserson L, Reich DL. A case of severe diffuse venous thromboembolism associated with aprotinin and hypothermic circulatory arrest in a cardiac surgical patient with factor V Leiden. Anesthesiology 2006;105:219-21
24. Augoustides JG, Lin J, Gambone AJ, Cheung AT. Fatal thrombosis in an adult after thoracoabdominal aneurysm repair with aprotinin and deep hypothermic circulatory arrest. Anesthesiology 2005;103:215-6
25. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004;18:245-259
26. Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin Hematol 2007;14:225-9
27. Hoffman M, Monroe DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003;49:14-21
28. Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007;83:707-14
29. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 2003;361:201-5
30. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85
31. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8
32. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006;46:919-33
33. Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 2004;98:1635-9